| abstract |
The present invention is based, in part, on the discovery of a family of antibodies that specifically bind human T cell immunoglobulin and mucin domain 3 (TIM-3). More specifically, the invention relates to methods of treating cancer by administering an anti-TIM-3 antibody in combination with an anti-PD-L1/TGF β trap fusion protein. The antibody inhibits or reduces tumor growth in a human patient or an animal model when administered to the human patient or animal model. |